Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions (Dietary Supple)

Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software

The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.

The main questions it aims to answer :

• What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
• Are there any potential drug interactions between dietary supplements and anticancer medications?

Participants will:

• Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
• Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
• Report any perceived adverse effects related to dietary supplement use to assess tolerance.
• Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.

Study Overview

• Status: Recruiting
• Conditions: Interaction Drug Food; Cancer (Solid Tumors)
• Intervention / Treatment: Behavioral: Dietary Supplement Use Assessment

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Sihame Lkhoyaali, Professor of Medical Oncology; Phone Number: +212 668-270035; Email: slkhoyaali@cm6.ma
• Study Contact Backup: Name: Badiaa Batlamous; Phone Number: +212 693572066

Study Locations

• Morocco
  • Rabat, Morocco
    • Recruiting
    • Institut National d'Oncologie
    • Contact: Sihame Lkhoyaali, Professor of Medical Oncology; Phone Number: +212 668-270035; Email: slkhoyaali@cm6.ma

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients diagnosed with cancer and receiving medical anticancer treatment (chemotherapy, hormone therapy, immunotherapy, or targeted therapy) at the study site. Participants will be assessed for dietary supplement use, tolerance, and potential interactions between dietary supplements and anticancer medications.

Description

Inclusion Criteria:

• Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
• Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
• Adult patients : >=18

Exclusion Criteria:

• Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
• Failure or refusal to provide written informed consent.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cancer Patients Using Dietary Supplements	Behavioral: Dietary Supplement Use Assessment; Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of Dietary Supplement Use and Tolerance	Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.	At enrollment
Potential Drug-Supplement Interactions	Assessment of potential interactions between dietary supplements and anticancer medications	At enrollment or single study visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Potential Drug-Supplement Interactions Assessed by Artificial Intelligence	Assessment of potential interactions between dietary supplements and anticancer treatments using Hedrine software.	At enrollment or Single study visit

Collaborators and Investigators

• Sponsor: Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2025
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: June 19, 2026
• First Submitted That Met QC Criteria: June 19, 2026
• First Posted (Actual): June 26, 2026

Study Record Updates

• Last Update Posted (Actual): June 26, 2026
• Last Update Submitted That Met QC Criteria: June 19, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: cancer; dietary supplements; Anticancer Therapy
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: ONCOSUPP-2026-08; CE/UM6SS/18/2025 (Other Identifier: Ethics Committee of Mohammed VI University of Health and Science (UM6SS), Casablanca, Morocco)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No